Cancer Genetics, Inc. Nasdaq (CGIX) · Investor Presentation | 2015 Cancer Genetics, Inc. | |...
Transcript of Cancer Genetics, Inc. Nasdaq (CGIX) · Investor Presentation | 2015 Cancer Genetics, Inc. | |...
Investor Presentation May 2015
Cancer Genetics, Inc. Nasdaq (CGIX)
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 2
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended March 31, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
Forward-Looking Statement
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 3
Fact Sheet
Market Cap $110.08 Mn
Stock Price $11.29 [6/04/2015]
Ticker Symbol Nasdaq: CGIX
Qtrly Revenue (yoy) 117.6%
Total Cash $28.6 Mn
Facilities • Rutherford, NJ • Raleigh, NC • Hyderabad, India • Shanghai, China
18,000 sq. ft. 28,000 sq. ft. 14,000 sq. ft. 3,000 sq. ft.
Clients • Cancer Centers • Physician Offices • Research Orgs.
• Hospitals • Biotech • Biopharma
Products 9 Launched Products Patents 8 US Issued Patents
Cancer Genetics, Inc.
*Financial data as of 5/12/2015
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 4
Recent Highlights 2014-2015
§ Agreement with Three Rivers Provider Network expanded
§ FHACT® partnership with PathAdvantage
§ Partnership with AstraZeneca to provide biomarker & MDx testing
§ Biopharma contracts increased to $30 Mn+
§ NYS licensure for FHACT®
§ Agreement with America’s Choice Provider Network®
§ Focus::CLL™ selected for use in global clinical trial by leading biotech company
§ Acquisition of Gentris Corporation
§ Acquisition of BioServe India
§ Collaborative kidney cancer study with Cleveland Clinic results announced
§ Collaborations with Keck Medicine of USC & Beth Israel Deaconess Medical Center for diffuse large B-cell lymphoma
§ Next Gen Sequencing Collaboration with Columbia University for myelodysplastic syndromes & acute myeloid leukemia
§ Multi-Year Collaboration with Moffitt Cancer Center for genomics-based prediction of chemotherapy side effects
Acquisitions Research
Collaborations Business Growth
§ Awarded additional kidney cancer patent for UroGenRA®-Kidney
§ Awarded two cervical cancer patents for FHACT®
§ Launch of MatBA®-FL & MatBA®-MCL for follicular lymphoma & mantle cell lymphoma
§ Launch of CALR mutation test for acute leukemias & myeloproliferative neoplasms
§ Upgraded MatBA®-CLL/SLL algorithm for patient stratification; add’l CLIA & NYS Licensure
§ Launch of Focus::CLL™, Focus::Myeloid™, & Focus::Hotspot™ NGS panels
Product Launches Patents
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 5
Business Overview
8 Genomic Tests Launched
Research & Development Biotech/Biopharma
3,622 5,946 6,871
11,912
2011 2012 2013 2014
Clinical Test Volume (2011-2014)
17 Current Research Collaborations
Clinical Laboratory
NGS Panel Development:
Contracts with 6 of the top 10 pharma companies
Hematologic Cancers:
Urogenital Cancers:
Cervical Cancer:
35% CAGR
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 6
Genomic Testing has Paved the Way for Significant Advancements in Diagnosis & Targeted Treatment Options
Comprehensive Report
Proprietary Products
Focused Oncology Lab
OUR INTEGRATED APPROACH TO MOLECULAR TESTING BRINGS BENEFITS ACROSS THE ENTIRE
ONCOLOGY ECOSYSTEM
DIAGNOSIS Do I have cancer and if so,
what type?
PROGNOSIS What course will my cancer take? What should I expect?
THERANOSIS What are my treatment
options? Which drug is the best fit for me?
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 7
We are Positioned to be the Oncology Diagnostics Partner of Choice in Attractive Markets
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
U.S.
China
India
$6 Bn
$1 Bn
N/A
Clinical
$2.5 Bn
$0.4 Bn
$1 Bn
Biopharma
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 8
Major Drivers for our Proprietary Programs
Is there an unmet patient need?
Is it unique & can it drive an IP-ready position?
Can we leverage the existing routine sample?
Can we validate and collaborate with major research centers?
Can it be offered as part of our Complete™ programs?
1
2
3
4
5
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 9
Eight US Patents Awarded
7 Proprietary Diagnostic Products Addressing 1.2 Mn Cases Globally Launched & in Market
Hematologic Cancers Cases per Year (global) CGI Test
Chronic Lymphocytic Leukemia 106,770 Focus::CLL™, MatBA®-CLL/SLL
Diffuse Large B-Cell Lymphoma 142,360 MatBA®-DLBCL
Follicular Lymphoma 62,300 MatBA®-FL
Mantle Cell Lymphoma 17,795 MatBA®-MCL
Urogenital Cancers Cases per Year (global) CGI Test
Kidney Cancer 340,000 UroGenRA®-Kidney
Cervical Cancer Cases per Year (global) CGI Test
Cervical Cancer 528,000 FHACT®
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 10
Significant Progress in Targeted NGS Panel Pipeline
* Oncospire Genomics: a joint venture with Mayo Clinic
RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY
FOCUS::CLL™
FOCUS::MYELOID™ (IN COLLABORATION WITH ILLUMINA)
FOCUS::LYMPHOID™
MULTIPLE MYELOMA (VIA ONCOSPIRE*)
FOLLICULAR LYMPHOMA (VIA ONCOSPIRE*)
HEMATOLOGIC CANCERS
FOCUS::RENAL™
UROGENITAL CANCERS
FOCUS::HOTSPOT™ (INITIAL LAUNCH IN INDIA)
LUNG CANCER (VIA ONCOSPIRE*)
SOLID TUMOR
COMPREHENSIVE PHARMACOGENOMICS PANEL
PHARMACOGENOMICS (PGX)
TEST IN MARKET
TEST IN MARKET
TEST IN MARKET
11 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
OncoSpire Genomics Developed by Cancer Genetics, Inc. and Mayo Clinic
§ World class NGS facility § Best in class bioinformatics § Immediately integrated into care
§ Disease focus and stewardship § Commercial focus and mgmt § Capital access and investment
SELECTED PROJECTS HAVE THE POTENTIAL TO BECOME CLINICAL STANDARD OF CARE IN NGS-BASED ONCOLOGY MANAGEMENT
§ Only Joint Venture by the Mayo Clinic in the Oncology space
§ Core operations leverage Mayo facilities in Rochester, MN
§ $1M funded in 2013 to initiate JV, $2M in 2014, up to $3M additional based on milestones
§ Projects with 12 to 30 month development horizon; Multiple Myeloma panel to launch in 2015
200,000 new cases
20,920 new cases
1.6 million new cases
Informed Discovery
Clinical Development
Commercial Development
Market Entry (with partners)
Multiple Myeloma
Follicular Lymphoma
Lung Cancer
12 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
Multiple Myeloma: Setting the New Standard with a Focused NGS Panel
A comprehensive NGS-based panel will be developed to…
To target a major unmet need growing globally:
Identifying MGUSs that need follow-up & Tx and determining best treatments for malignancies
Provide Greater Certainty & Reduce Complexity of Diagnosis àReplaces cyto, FISH & gene expression profiling 1.
2. Earlier, More Accurate, Cost-Effective Prediction of MM àIdentify mutations that predict change from MGUS to MM
• 88 genes selected for panel
• DNA sequencing complete for first 60 samples
• Analysis underway comparing 3 different analytical methods to determine best solution
• In process of optimizing clinical laboratory design from extraction to reporting solution
• 3 papers in the publication process
• 2 international early-access collaborations established
13 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
Focus::CLL™ NGS Panel
§ Launched in Q4 2014
§ Unique targeted NGS panel with 7 biomarkers for diagnosis, prognosis and patient management
§ The only targeted NGS panel available for CLL/SLL
§ Selected for use in global clinical trial by a leading biotechnology company
§ 18,200 new cases per year § 150,000 people living with the disease
Numbers Behind the Disease
§ Chronic Lymphocytic Leukemia (CLL) § Small Lymphocytic Lymphoma (SLL)
Clinical Indications
(United States)
http://www.cancergenetics.com/laboratory-services/specialty-tests/focus-ngs/focuscll/
14 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
Focus::Myeloid™ NGS Panel
§ Launched in Q1 2015 § Comprehensive NGS panel with 54 biomarkers that provides actionable information
for improved diagnosis, prognosis, and risk stratification
§ Delivers faster results on biomarkers in current diagnostic and treatment guidelines
§ Expands therapy options for patients with appropriate enrollment in clinical trials
§ Selected for use in multiple clinical trials
§ 54,000 new cases per year § 274,000 people living with the disease
Numbers Behind the Disease
§ Acute myeloid leukemia (AML) § Myelodysplastic syndrome (MDS) § Myeloproliferative neoplasms (MPN)
Clinical Indications
(United States)
http://www.cancergenetics.com/laboratory-services/specialty-tests/focus-ngs/focusmyeloid/
15 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
MatBA®-CLL/SLL Drives Improved Management of Patients with Chronic Lymphocytic Leukemia (CLL)
Favorable/ Intermediate (no distinction)
Unfavorable 85%
15%
FISH 4 Genomic Aberrations
Risk stratification by FISH, classifies patients into only two groups:
§ Favorable/Intermediate (no distinction)
§ Unfavorable
38% of cases are favorable falling under "watch & wait" approach.
8% of unfavorable cases missed by FISH are caught by MatBA®-CLL/SLL. 23%
39%
38%
20 Genomic Aberrations Favorable
Intermediate
Unfavorable
MatBA®-CLL/SLL is both CLIA & NYS licensed to stratify patients into three distinct risk groups:
§ Favorable § Intermediate § Unfavorable
16 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
[Kanti Rai, Nicholas Chiorazzi, Jacqueline Barrientos]
Significance of Current Prognostic Markers in CLL in the B-Cell Receptor Signaling Pathway Inhibitor Era
Zydelig™ [Idelalisib (PI3K-delta)]
§ FDA Approved For CLL in the relapse setting when considering Rituximab alone
§ Collaborative project in progress at CGI
§ Insights will be integrated into our CLL Complete™
IMBRUVICA™ [Ibrutinib (BTK)]
§ FDA Approved for CLL with 17p loss and in the relapse setting where two prior therapies have failed
§ Genomic alterations associated with resistance Ø Acquired Mutations during therapy in BTK
Gene (C481S), PLCG2 (R665W) Ø Deletion of 8p Ø Gain of 3q
B-CELL RECEPTOR SIGNALING PATHWAY INHIBITORS
17 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
Solution
UroGenRA®-Kidney Can Guide Management of Patients with Renal Masses and Appropriate Treatment Selection
Development of diagnostic algorithm § >600 RCC malignant subtypes (in-silico: SNP) § >100 malignant and benign renal neoplasms (in-house: aCGH & FISH)
Retrospective in-house FFPE validation (n>190) CCF diagnostic yield
diagnostic sensitivity to distinguish benign from malignant renal neoplasms sensitivity to distinguish malignant RCC subtypes
Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC § Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to
surgical intervention
Men and women with renal masses often undergo unnecessary nephrectomy for accurate diagnosis and experience delay in treatment
Problem UroGenRA® will detect genomic aberrations in a single assay permitting accurate diagnosis (benign vs malignant, and malignant subtype) guiding appropriate management and treatment strategies
[C. Magi-Galluzzi and E. Klein]
[J. Coleman and J. Durack]
18 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
FHACT® Fits Directly into Today’s Cervical Cancer Screening Workflow
Today, all these women are referred for colposcopy.
Not referred for colposcopy
Referred for colposcopy
PROGRESS to a higher grade and increased risk for cancer within 10-30 years of the infection.
REGRESS within 2 years of the infection.
FHACT® Results: Normal
FHACT® Results: Abnormal
§ Today, all HPV+ women with abnormal
Pap results are referred for colposcopy § Several cervical cancer tests are
available but the need for less invasive and better informed treatment exists
§ FHACT® helps triage before colposcopy
§ No resampling § Fewer women referred for colposcopy § Reduced healthcare costs
19 Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics
FISH-based HPV-Associated Cancer Test FHACT® assesses non-random genomic alterations associated with progression of lesion.
§ Gain of 3q26 (TERC) has been detected with increasing frequency in cervical lesions with increasing severity and is observed in about 75% of cervical cancers.[1-2]
§ Gains of 5p15, 20q13 & chr 7 share a similar pattern of appearance in precancerous cytology specimens by FISH (40-45%, 20q13, and 15% respectively).[3-4]
§ Performed on remnant liquid based cytology. § Gain at any of the FHACT® loci is detected in up to 89.5% of all
cervical cancers.[5]
FHACT® presents the highest sensitivity on the market (4 loci).
1. Heselmeyer-Haddad K, et al. (2005). Am. J. Pathol. , 166, 1229-1238
2. Seppo A., et al. (2009) Gynecol Oncol, 114, 80-83 3. Scotto, L., et al. (2008). Mol Cancer, 7, 58. 4. Luhn P, et al. (2013). Gynecol Oncol, 130, 595-600. 5. The Cancer Genome Atlas (TCGA) (http:/cancergenome.nih.gov)
FHACT® Can Aid in Identifying Women with Markers of High Grade Lesions (Cervical Cancer)
FHACT® Loci: § 3q26 gain (red)
§ 5p15 gain (green)
§ Cen7 (aqua)
§ 20q13 gain (gold)
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 20
Community Hospitals Regional Cancer Centers
Oncologists and Pathologists
• Continue to growing sales force that calls on hospitals and regional laboratories
• Plan development of national footprint through Expand Dx™
Biotechnology Companies Pharmaceutical Companies
• Leverage clinical infrastructure and proprietary product portfolio for testing services that support clinical trials
• Expand sales emphasis of Select One®
Emerging Markets • Enhance distributor base in select emerging economies • Partner with leading local cancer care providers and
hospitals to provide probes, arrays and clinical services
• Collaborate to create and validate microarrays and other proprietary products
• Accelerate launch of large scale studies Universities and Research Centers
Large, Targeted Market Opportunities
Commercialization Strategy Target Markets
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 21
• Delivers better outcomes to community hospitals and laboratories
• Enables community hospitals to bring “state-of-the-art” genomic testing to patients
• Brings personalized medicine to the community hospital vs. just at academic and teaching hospitals
• Allows community hospitals to keep patients and treat them locally
• Improving care and quality is critical to maintaining reimbursement for community hospitals
$600,000 - $800,000 USD in Testing Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals & Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially Diagnosed in Community Hospitals & Laboratories
Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 22
Strong Growth in Clinical Trial Contracts with Oncology Programs at Leading Biotech & Pharma Companies
Approximate expected future revenues under signed contracts with biotechnology and pharma customers for testing and services to support currently planned clinical trials.
CGI IS ACTIVELY PROVIDING TESTING, GENOMIC SERVICES, AND BIOMARKER SUPPORT FOR
December 2013 December 2012 December 2014 March 2015
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 23
Strong History of Growth Revenue Trends (2014 Year End and Q1 2015)
Year End Total Revenue ($Mn) Q1 Total Revenue ($Mn)
§ $10.2 Mn revenue, up 54% Yr./Yr. § Biopharma revenue grew 112% Yr./Yr.
$[VALUE]
$[VALUE]
$[VALUE]
10.2
2011 2012 2013 2014
$
36% CAGR
2014 2013 2011 2012
§ $4.4 Mn revenue, up 206% Qtr./Qtr. § Biopharma revenue grew 578% Qtr./Qtr.
$[VALUE]
$[VALUE]
$[VALUE]
$[VALUE]
Q1, 2012 Q1, 2013 Q1, 2014 Q1, 2015 Q1, 2015 Q1, 2014 Q1, 2013 Q1, 2012
53% CAGR
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 24
Summary Statement of Operations
Income Statement Item ($ in Thousands) Q1 2013 Q1 2014 Q1 2015 Revenue $1,219 $1,430 $4,370
Gross Profit 149 140 1,229
Gross Margin (%) 12% 10% 28%
Research & Development (R&D) 491 597 1,278
Sales & Marketing (S&M) 397 749 1,116
General & Administrative (G&A) 1,571 2,731 2,987
Operating Profit (Loss) (2,309) (3,936) (4,152)
Net Income (Loss) 2,360
(2,486) (4,278)
Balance Sheet Information Actual 03/31/15 All Cash* $28,612 Stockholders’ Equity 30,972 $ in thousands * All cash includes $6,300 of restricted cash.
$6,000 of that is now unrestricted as of May 7, 2015. (Cancer Genetics, Inc. 2014 YE 10Q, page 77)
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 25
Revenues by Category
76%
20%
4% Q1 2015
BIOPHARMA SERVICES
CLINICAL SERVICES
DISCOVERY SERVICES $10.2 Mn $4.4 Mn
§ Launched new NGS panels, including Focus::Myeloid™
§ Repositioning of Go-To Market Strategy to concentration on clinical sales
§ New research studies with leading cancer centers and academic institutions
§ Focus::Hotspot™ NGS panel for solid tumors adopted in multiple research programs in India
§ Selected to power molecular and biomarker testing for six clinical trials
§ Focus::CLL™ chosen for global clinical trial by leading biotechnology company
$3.3 M
$873 K
$166 K
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 26
Consistent Achievement of Milestones Expected in Coming Quarters
§ Increasing covered lives market access through additional payers & health care organizations § Additional international agreements for FHACT® distribution and co-marketing partnerships in key geographies
§ Launching multi-marker NGS panel for lymphoid malignancies § Multiple Myeloma NGS panel launch, Oncospire à Second half of 2015
§ Lymphoid, Myeloid and CLL Panels - Additional data and results to support clinical usage, patient value and payor coverage
§ FHACT® - Additional data from a study conducted in conjunction with NCI and more published papers focused on FHACT®, including a health economic study
§ Additional news on biopharma partners & relationships § Major collaborations with US & Asia biopharma companies
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 27
Scientific Advisory Board Andrea Califano, Ph.D. Chairman of the Columbia Initiative for Systems Biology Associate Director for Bioinformatics, Herbert Irving Comp. Cancer Ctr
Timothy A. Chan, M.D., Ph.D. Principal Investigator, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D. Director, Institute for Cancer Genetics at Columbia University
Vundavalli V. Murty, Ph.D. Director, Cancer Cytogenetic Laboratory and Molecular Pathology at Columbia University
Hans-Guido Wendel, M.D. Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-Kettering Cancer Center
Howard McLeod, PharmD Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Andrew D. Zelenetz, M.D., Ph.D. Chief of Lymphoma Service and Head of Molecular Hemo-Oncology Laboratory, Department of Medicine at MSKCC
Panna Sharma President & CEO • 15+ years as advisor to global life science & healthcare cos. • General Manager of Oncospire Genomics, JV with Mayo Clinic • Founded TSG Partners • Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer • 30+ yrs in finance & deal making in the healthcare industry • Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation
(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D • 25+ years in translational oncology research • Published 50+ articles, 4 patents • NIH grantee
Rob Fannon Vice President of Operations • 10+ years operations, client management, molecular test & panel
development, and biorepository management • Roche Molecular Systems, BioServe Biotechnologies, Ltd., Stansberry &
Associates Investment Research
John Pappajohn [Chairman] | Edmund Cannon | Raju Chaganti, Ph.D. | Geoffrey Harris
Howard McCleod, Pharm.D. | Franklyn Prendergast, M.D., Ph.D. | Panna Sharma | Michael J. Welsh M.D.
Board of Directors
Officers & Management Team
Experienced and Focused Management and Boards
Investor Presentation | 2015 Cancer Genetics, Inc. | www.cancergenetics.com | @Cancer_Genetics 28
• Strong and growing portfolio in molecular-focused patents for disease identification & stratification
• IP-based on unique algorithms across a broad group of chromosomal regions
• Validation of specific clinical endpoints that are associated with particular disease outcomes or decisions
• Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms • US Issued Patent 8,580,713 • US Issued Patent 8,557,747 • Europe 10803548.6 • India 6657/DELNP/2012 • Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)
• US Issued Patent 7,585,964 • US Issued Patent 7,964,345 • Canada 2,447,320 – Foreign Counterpart Patent
Panel for the Detection & Differentiation of Renal Cortical Neoplasms • US Issued Patent 8,603,948 • US Issued Patent 8,716,913 • Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated Cancers
• US Issued Patent 8,865,882 • US Issued Patent 8,883,414 • PCT/US2011/050681
Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers
• US 61/581,350
IP Position and Detailed Global Strategy
Thank you Nasdaq (CGIX)
CGI Headquarters Meadows Office Complex 201 Route 17 North, 2nd Fl. Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235
RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court, S.400 Morrisville, NC 27569 Phone: +1 919-465-0100 Fax: +1 919-465-0554
RALEIGH, NC #3-1-135 / 1A CNR Complex Mallapur Main Road, R.R. Dst. Hyderabad – 500 076, Telangana Toll-free: +91 040-2717-8178 Fax: +91 040-2717-8176
HYDERABAD, INDIA 781 Cai Lun Road, Room 803 Shanghai 201203 P.R. China Toll-free: +91 040-2717-8178 Fax: +91 040-2717-8176
SHANGHAI, CHINA
For further information, please contact us at [email protected]